SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
To determine the clinical response rate of everolimus in combination with bevacizumab for
patients with chemotherapy refractory sporadic or neurofibromatosis type 1 (NF1) associated
malignant peripheral nerve sheath tumor (MPNST). To evaluate the toxicity and safety of
everolimus in combination with bevacizumab in individuals with MPNST
Phase:
Phase 2
Details
Lead Sponsor:
Sarcoma Alliance for Research through Collaboration
Collaborators:
Genentech, Inc. Novartis Pharmaceuticals United States Department of Defense